1. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer.
- Author
-
El Hejjioui, Brahim, Lamrabet, Salma, Amrani Joutei, Sarah, Senhaji, Nadia, Bouhafa, Touria, Malhouf, Moulay Abdelilah, Bennis, Sanae, and Bouguenouch, Laila
- Subjects
- *
TRIPLE-negative breast cancer , *DNA repair , *BIOMARKERS , *HER2 gene , *HORMONE receptor positive breast cancer , *GENE amplification - Abstract
Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer lacking hormone receptor expression and HER2 gene amplification. TNBC represents a heterogeneous subtype of breast cancer, characterized by poor prognosis, high invasiveness, high metastatic potential, and a tendency to relapse. In this review, the specific molecular subtypes and pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the biomarker characteristics of TNBC, namely: regulators of cell proliferation and migration and angiogenesis, apoptosis-regulating proteins, regulators of DNA damage response, immune checkpoints, and epigenetic modifications. This paper also focuses on omics approaches to exploring TNBC, such as genomics to identify cancer-specific mutations, epigenomics to identify altered epigenetic landscapes in cancer cells, and transcriptomics to explore differential mRNA and protein expression. Moreover, updated neoadjuvant treatments for TNBC are also mentioned, underlining the role of immunotherapy and novel and targeted agents in the treatment of TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF